NEWS
23 Jan 2025 - Performance Report: Bennelong Twenty20 Australian Equities Fund
[Current Manager Report if available]
23 Jan 2025 - Trump nominated a vaccine sceptic for health secretary. What does that mean for investors?
|
Trump nominated a vaccine sceptic for health secretary. What does that mean for investors? Redwheel December 2024 |
|
Vaccines are among the most impactful medical inventions in history.[i] Globally, vaccines exist to prevent more than 20 life-threatening diseases.[ii] New estimates suggest that global immunisation efforts over the past 50 years have prevented 154 million deaths from diseases like diphtheria, tetanus, pertussis, yellow fever, and measles.[iii] Despite worldwide immunisation success, the COVID-19 outbreak and resulting vaccination race brought into focus the global prevalence of vaccine hesitancy and appeared to trigger a further decline of trust in vaccinations.[iv] A US survey found that the proportion of surveyed adults who do not think approved vaccines are safe rose by 6% to 16% between 2021 and 2023.[v] Similarly, a survey in Germany shows that public vaccine scepticism increased from 21% in 2022 to 25% in 2024.[vi] As a result of decreasing vaccine uptake and concerns over the prevalence of preventable diseases, the World Health Organisation has declared vaccine hesitancy as one of the top global health challenges.[vii] Whooping cough (pertussis) in England shows the concerning effect of increasing vaccine scepticism, declining vaccination rates, and consequent rising incidence of the disease. Although historically associated with lower-income countries where there is greater mistrust of vaccines, Figure 1 demonstrates how growing scepticism can have a marked impact on disease prevalence in higher-income countries too[viii]. In 10 years, the infant pertussis vaccine coverage in England fell from 94% to 91%, meanwhile the maternal pertussis vaccine coverage fell from 75% to 59% from 2017 to 2024[ix]. Incidence of the disease has more than tripled over the same time-period. 
A similar trend can be detected with measles, where misguided concerns over a link with autism in children have led to declining vaccination rates[x]. 2023 saw a 20% rise in global cases compared to 2022[xi], while nearly 60 countries experienced outbreaks in the past year. Globally, only 83% of children received a first dose of the measles vaccine in 2023 and only 74% received the recommended second dose, despite national coverage of 95% or greater being necessary to prevent outbreaks of the contagious disease.[xii] During the COVID-19 pandemic it was found that antivaccine messages from authority figures were a common reason for vaccine hesitancy.[xiii] Now that President-elect Donald Trump has nominated Robert F Kennedy Jnr. (RFK Jnr.) - who has been skeptical of vaccines in the past - to head up the Health and Human Services Department, there are increasing concerns of an even greater erosion of people's willingness to get vaccinated in the US.[xiv] How does this impact investors? RFK Jnr.'s nomination as Head of Health and Human Services (HHS) precipitated a sharp sell-off in healthcare stocks. Sanofi, Merck, Pfizer, GSK, and Moderna have greater exposures to the US vaccine market and hence were punished most by the market in the week of his nomination. 
Although there is very little clarity over the shape of future US health policy, there is a presumption in the investment community that RFK Jnr.'s vaccine stance may lead to larger and longer clinical trials, stricter labels for approved products, lower vaccination rates, and therefore lower revenues for vaccine makers. Further, with Republican control of both chambers of Congress and the White House, a hawkish health department could seek to repeal the National Childhood Vaccine Injury Act of 1986 which protects vaccine makers from litigation due to injury. An increase in lawsuits - even if not successful - may increase costs for manufacturers. Ultimately, if significant legislative changes were to occur then investing in vaccine makers could be riskier. However, whilst commentators have focussed largely on RFK Jnr.'s more harmful rhetoric, not all news has been entirely negative. RFK Jnr. has stated that vaccines were 'not going to be taken away from anybody'[xv], while Vivek Ramaswamy - who will co-lead the newly created Department of Government Efficiency (DOGE) - confirmed that the new US healthcare leadership 'understand innovation is a key part of the solution.'[xvi] And it is interesting to note that Ramaswamy has made comments suggesting that he wants DOGE to reduce regulatory burden on pharma, biotech and medical device companies that require US Food and Drug Administration (FDA) approval. He recently posted on X, "My #1 issue with FDA is that it erects unnecessary barriers to innovation", so it could be argued that the FDA under the Trump administration may be supportive of getting treatments to patients more quickly, which would most likely be a net positive for manufacturers. Further, it is our view that despite potential disruption in US healthcare, many treatments will continue to have a life-changing impact on patients' lives, and hence, best-in-class businesses will keep their competitive advantage. In the week of RFK Jnr.'s nomination, the MSCI AC World Health Index declined by more than 5%[xvii], which included companies with no exposure to vaccines. With that discount, we believe there are significant opportunities for us to invest in these life-changing solutions at compelling valuations. 
|
|
Funds operated by this manager: Redwheel China Equity Fund, Redwheel Global Emerging Markets Fund |
|
Sources: [i] UN, 2024 [ii] WHO, 2024 [iii] WHO, 2024 [iv] Larson et al., 2022 [v] Annenberg Public Policy Center, 2023 [vi] Statista, 2024 [vii] WHO, 2019 [viii] RACGP, 2024 [ix] GOV UK, 2024 [x] Hviid et al., 2019 [xi] Reuters, 2024 [xii] CDC, 2024 [xiii] Griffith et al., 2021 [xv] NPR interview, 06/11/2024. [xvi] Vivek Ramaswamy's push for FDA changes could boost his wealth - The Washington Post, accessed 27/11/2024. [xvii] Bloomberg, November 2024 Key Information |
22 Jan 2025 - Performance Report: Altor AltFi Income Fund
[Current Manager Report if available]
22 Jan 2025 - Long-term Investing
|
Long-term Investing Airlie Funds Management December 2024 |
|
Investing in Australian listed companies with a long-term outlook entails retaining investments for a minimum of five years or longer. While the exact time frame for long-term investing can differ, the core principle is dedication, regardless of market turbulence and fluctuations in asset prices. We delve into key strategies tailored for those investors keen on harnessing the potential of Australian listed companies for long-term wealth accumulation. Objectives, risk tolerance and investment horizonLong-term investing begins with a clear understanding of your financial objectives, risk appetite, and investment time frame. Whether your aim is to secure your retirement, finance education expenses or a dream property, clearly defining your goals is essential. Assessing your risk tolerance, which means finding out if your risk level is conservative, moderate or aggressive, helps you understand the level of risk you're willing to accept in pursuit of your investment objectives. Generally, investors with longer horizons can afford to embrace higher risks compared to those nearing retirement. It's important to consider your investment time horizon, as this is when you'll need access to money to achieve your financial objectives. Some of the factors that influence your time horizon include your financial goals, income, age and risk tolerance. Tailoring your investment strategy to align with your unique circumstances is foundational for long-term success in the Australian market. Diversify your portfolioThe Australian investment landscape, like any other, is prone to unpredictability and market fluctuations. Spreading your investments across different industry sectors can potentially help to mitigate risk. Diversification may help reduce the potential negative impact of any single asset's downturn on your overall portfolio. This approach helps in balancing out the performance, as when one asset or sector underperforms, another may outperform, stabilising the portfolio's returns. It's important to align diversification with your individual risk tolerance and investment goals, ensuring a well-rounded and resilient investment strategy. Stay committedEmotions often run high during market downturns, tempting investors to deviate from their chosen investment strategies. However, succumbing to fear-driven decisions can jeopardise long-term returns. Resist the urge to time the market, as consistently predicting market movements is exceedingly challenging. Long-term investing requires discipline and resilience, where investors are encouraged to adhere to their investment strategies even amidst turbulent market conditions. Avoid falling into the trap of chasing short-term profits, as maintaining investment during market cycles can be essential for realising the full potential of the market. It's easy to feel drawn to timing the markets, aiming to choose tomorrow's winners from yesterday's winners. However, evidence suggests that market timing is a tough game. Take the buy low, sell high approach, for instance; it hinges on predicting when a stock will rise or fall, a task fraught with complexity. Successful long-term investing, on the other hand, demands a commitment to staying invested, resisting the urge to constantly chase the next big thing. The chart below illustrates the risks of trying to time the market.
Leverage expertise and regular reviewAchieving success in investing requires a thorough understanding of market dynamics and investment strategies. Consider investing in managed funds where investment experts are actively researching and managing a portfolio, aiming for optimal diversification with continued dedicated oversight. Review your investment strategy regularly to ensure it remains aligned with your long-term objectives. Rebalancing your portfolio and adjusting the weightings of your portfolio helps to ensure alignment with your intended long-term goals. Over time, some investments may perform better than others, causing your portfolio to shift from its original strategy. Rebalancing brings your portfolio back to its original plan, ensuring it continues to reflect your investment goals and risk tolerance. Long-term investing in Australian-listed companies entails a strategic approach tailored to your unique financial goals and risk tolerance. By embracing diversification, maintaining discipline, and leveraging expert guidance, investors may have greater confidence in navigating the dynamic Australian market landscape. Funds operated by this manager: Airlie Australian Share Fund, Airlie Small Companies Fund Important Information: This material has been delivered to you by Magellan Asset Management Limited ABN 31 120 593 946 AFS Licence No. 304 301 trading as Airlie Funds Management ('Airlie') and has been prepared for general information purposes only and must not be construed as investment advice or as an investment recommendation. This material does not take into account your investment objectives, financial situation or particular needs. This material does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should obtain and consider the relevant Product Disclosure Statement ('PDS') and Target Market Determination ('TMD') and consider obtaining professional investment advice tailored to your specific circumstances before making a decision about whether to acquire, or continue to hold, the relevant financial product. A copy of the relevant PDS and TMD relating to an Airlie financial product or service may be obtained by calling +61 2 9235 4760 or by visiting www.airliefundsmanagement.com.au. Past performance is not necessarily indicative of future results and no person guarantees the future performance of any financial product or service, the amount or timing of any return from it, that asset allocations will be met, that it will be able to implement its investment strategy or that its investment objectives will be achieved. This material may contain 'forward-looking statements'. Actual events or results or the actual performance of an Airlie financial product or service may differ materially from those reflected or contemplated in such forward-looking statements. This material may include data, research and other information from third party sources. Airlie makes no guarantee that such information is accurate, complete or timely and does not provide any warranties regarding results obtained from its use. This information is subject to change at any time and no person has any responsibility to update any of the information provided in this material. Statements contained in this material that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of Airlie. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. No representation or warranty is made with respect to the accuracy or completeness of any of the information contained in this material. Airlie will not be responsible or liable for any losses arising from your use or reliance upon any part of the information contained in this material. Any third party trademarks contained herein are the property of their respective owners and Airlie claims no ownership in, nor any affiliation with, such trademarks. Any third party trademarks that appear in this material are used for information purposes and only to identify the company names or brands of their respective owners. No affiliation, sponsorship or endorsement should be inferred from the use of these trademarks. This material and the information contained within it may not be reproduced, or disclosed, in whole or in part, without the prior written consent of Airlie. |
21 Jan 2025 - Performance Report: Skerryvore Global Emerging Markets All-Cap Equity Fund
[Current Manager Report if available]
21 Jan 2025 - Glenmore Asset Management - Market Commentary
|
Market Commentary - December Glenmore Asset Management January 2025 Globally, equity markets were broadly weaker in December. In the US, the S&P 500 declined -2.5%, the Nasdaq rose +0.5%, whilst in the UK, the FTSE fell -1.4%. December saw the US Federal Reserve cut interest rates (as expected), however guidance from the Fed regarding further rate cuts in 2025 was tempered, due to stubbornly high inflation and a strong US employment market. There is also potential for US president Donald Trump's "pro growth" policies to result in higher inflation over the next 12-24 months, which may have been a factor in the monetary policy guidance. Domestically, in line with its offshore peers, the ASX All Ordinaries Accumulation index declined, falling -3.1%. On the ASX, the top performing sectors were staples and utilities, with real estate being the main underperformer (impacted by higher bond yields). Resources also lagged due to weak sentiment towards the outlook for the Chinese economy. Bond markets saw yields increase in December as forward guidance for the number of interest rate cuts from the US based Federal Reserve was reduced. The US 10 year government bond yield climbed +30 basis points (bp) to close at 4.52%, whilst its Australian counterpart was flat +2bp to end the month at 4.37%. Funds operated by this manager: |
20 Jan 2025 - Performance Report: Bennelong Emerging Companies Fund
[Current Manager Report if available]
20 Jan 2025 - Performance Report: DS Capital Growth Fund
[Current Manager Report if available]
20 Jan 2025 - Performance Report: Quay Global Real Estate Fund (Unhedged)
[Current Manager Report if available]
20 Jan 2025 - New Funds on Fundmonitors.com
|
New Funds on FundMonitors.com |
|
Below are some of the funds we've recently added to our database. Follow the links to view each fund's profile, where you'll have access to their offer documents, monthly reports, historical returns, performance analytics, rankings, research, platform availability, and news & insights. |
 |
||||||||||||||||||||||
| HOPE Housing Investment Trust | ||||||||||||||||||||||
|
||||||||||||||||||||||
| View Profile | ||||||||||||||||||||||
| HOPE Housing Residential Property Trust | ||||||||||||||||||||||
|
||||||||||||||||||||||
| View Profile | ||||||||||||||||||||||
 |
||||||||||||||||||||||
| Fairlight Global Small & Mid Cap (SMID) Fund - Hedged | ||||||||||||||||||||||
|
||||||||||||||||||||||
| View Profile | ||||||||||||||||||||||
 |
||||||||||||||||||||||
| Labassa Capital Australian Real Estate Debt Fund | ||||||||||||||||||||||
|
||||||||||||||||||||||
| View Profile | ||||||||||||||||||||||
 |
||||||||||||||||||||||
| Capstone Income Fund | ||||||||||||||||||||||
|
||||||||||||||||||||||
| View Profile | ||||||||||||||||||||||
|
Want to see more funds? |
||||||||||||||||||||||
|
Subscribe for full access to these funds and over 900 others |
